CUTR
Cutera, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website cutera.com
- Employees(FY) 540
- ISIN US2321091082
Performance
-21.74%
1W
-57.72%
1M
-64.44%
3M
-86.38%
6M
-91.42%
YTD
-86.65%
1Y
Profile
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all body and skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and enlighten, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides excel HR, a hair removal solution for all skin types; and xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Technical Analysis of CUTR 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-11 19:00
- 2024-11-07 13:27
- 2024-11-07 04:35
Cutera (CUTR) Reports Q3 Loss, Misses Revenue Estimates(Yahoo Finance)
- 2024-11-07 03:29
Cutera: Q3 Earnings Snapshot(Yahoo Finance)
- 2024-11-07 03:01
Cutera Announces Third Quarter 2024 Financial Results(Businesswire)
- 2024-10-09 05:53
- 2024-10-07 06:48
- 2024-09-23 15:44
- 2024-08-08 18:40
- 2024-08-08 09:59
- 2024-08-08 05:40
Cutera (CUTR) Reports Q2 Loss, Misses Revenue Estimates(Yahoo Finance)
- 2024-08-08 04:38
Cutera: Q2 Earnings Snapshot(Yahoo Finance)
- 2024-08-08 04:01
Cutera Announces Second Quarter 2024 Financial Results(Businesswire)
- 2024-07-30 20:00
- 2024-07-30 20:00
- 2024-07-25 23:53
- 2024-06-30 18:15
- 2024-06-27 14:04
Why Are Hedge Funds Shorting Cutera, Inc. (CUTR)?(Insidermonkey)
- 2024-06-26 11:08
- 2024-06-12 20:30
- 2024-06-10 04:30
Cutera Appoints Jeryl L. Hilleman to Board of Directors(Businesswire)
- 2024-06-09 18:00
The 3 Most Undervalued Meme Stocks to Buy in June 2024(Investorplace)
- 2024-06-06 20:30
Cutera Announces AviClear Investor Webinar(Businesswire)
- 2024-06-06 02:57
- 2024-06-05 20:17
- 2024-05-30 05:57
- 2024-05-22 13:30
- 2024-05-16 05:00
- 2024-05-10 04:47
Cutera, Inc. (NASDAQ:CUTR) Q1 2024 Earnings Call Transcript(Yahoo Finance)
- 2024-05-09 05:20
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.